Description: Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Home Page: www.soligenix.com
SNGX Technical Analysis
29 Emmons Drive
Princeton,
NJ
08540
United States
Phone:
609 538 8200
Officers
| Name | Title |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of Directors, CEO & Pres |
| Mr. Jonathan L. Guarino CPA, CGMA | Sr. VP, CFO & Corp. Sec. |
| Dr. Oreola Donini Ph.D. | Sr. VP & Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Sr. VP & Chief Medical Officer |
| Mr. Richard L. Dunning | Exec. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 22.6189 |
| Price-to-Sales TTM: | 30.8559 |
| IPO Date: | 1987-06-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |